CSL Limited (CMXHF) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Melbourne, VIC, Australia. Der aktuelle CEO ist Gordon Naylor DipCompSc.
CMXHF hat IPO-Datum 2005-11-18, 32,698 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $46.79B.
CSL Limited is a global biopharmaceutical company founded in 1916 and headquartered in Parkville, Australia. The company researches, develops, manufactures, and distributes biopharmaceutical products across Australia, the United States, Europe, China, and other international markets. Operating through two main divisions—CSL Behring and Seqirus—the company specializes in plasma-derived therapies for immunodeficiency, bleeding disorders, and neurological conditions, as well as non-plasma biotherapeutics and influenza-related products. CSL Behring also generates revenue through licensing and royalties on intellectual property commercialization.
